Wordt geladen...
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies
Temozolomide, an oral cytotoxic agent with approximately 100% bioavailability after one administration, has demonstrated schedule-dependent clinical activity against highly resistant cancers. Thirty patients with minimal prior chemotherapy were enrolled in this phase I trial to characterize the drug...
Bewaard in:
| Hoofdauteurs: | , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Nature Publishing Group
1999
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2362937/ https://ncbi.nlm.nih.gov/pubmed/10576660 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6690802 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|